Spinraza

Selected form

Nusinersen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spinraza

What is Spinraza? Defining the Medicine and Its Purpose

Property	Description
Active ingredient	Nusinersen
Form	Sterile solution
Pharmacological class	RNA Splicing Modifier; Antisense Oligonucleotide (ASO)
General action	Increases production of functional SMN protein
Origin	Synthetic/Biotechnological Derivative

Spinraza is the trade name for the active ingredient Nusinersen, a sophisticated, synthetic medicine that acts as a gene-targeted therapy. This prescription-only treatment is classified as an Antisense Oligonucleotide (ASO) and is primarily defined by its unique action as an RNA Splicing Modifier. It represents a novel approach in pharmacology, being the first approved drug of its kind to address the specific genetic cause of its indicated conditions.

What is Nusinersen's Active Ingredient and Pharmacological Class?

The active compound, Nusinersen, belongs to the pharmacological class of RNA Splicing Modifiers and Antisense Oligonucleotides. Nusinersen is an SMN2-directed antisense oligonucleotide. This classification is based on its precise molecular action. Unlike many conventional small-molecule drugs, Nusinersen is designed to intervene at the level of genetic instruction, making it a highly specialized, targeted treatment.

What Type of Solution is Spinraza and What is its Composition?

Spinraza is prepared as a clear, colorless sterile solution intended exclusively for intrathecal injection. The product is a single-active ingredient therapy, consisting of Nusinersen dissolved in an aqueous solution of isotonic phosphate-buffered saline. The specialized intrathecal route of administration is used to deliver the active ingredient to the spinal cord and its target motor nerve cells. This specific form and administration method ensure the ASO reaches the central nervous system, where it is required.

What is the General Purpose of Nusinersen's Action?

The fundamental purpose of Nusinersen is to address a genetic deficiency by modifying the splicing process of the SMN2 gene. This mechanism, known as RNA splicing modulation, increases the cellular production of the full-length Survival Motor Neuron (SMN) protein. By compensating for the genetic shortfall and restoring levels of this essential protein, the medicine helps support the health and function of the body's motor nerve cells, which are responsible for muscle movement and strength.

Regulatory References

EMA EPAR for Spinraza

What side effects are possible with Spinraza?

Possible Side Effects and Safety Information

The official safety profile for Spinraza (Nusinersen) is structured around adverse reactions reported in clinical studies and documented through post-marketing surveillance, distinguishing between reactions more common in infantile-onset versus later-onset Spinal Muscular Atrophy (SMA) patients.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are often associated with the intrathecal administration procedure (lumbar puncture).

Category	Common Reactions (Based on regulatory classification)
Infections	Lower respiratory infection, upper respiratory infection
Procedure-Related	Headache, Back pain, Vomiting, Post-lumbar puncture syndrome
General	Pyrexia (fever), Constipation

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight specific serious adverse reactions and safety considerations related to the drug's mechanism and class (Antisense Oligonucleotide or ASO).

Specific serious reactions include potential renal toxicity, such as glomerulonephritis, and coagulation abnormalities including acute severe thrombocytopenia (low platelet count). Cases of communicating hydrocephalus and aseptic meningitis have also been reported. Due to the potential for bleeding complications, the official safety information requires monitoring of platelet counts and coagulation parameters prior to each administration, as well as periodic monitoring of kidney function.

Adverse reactions associated with the lumbar puncture procedure typically occur within 72 hours of the injection. In infants and pediatric patients, official labels note an observation of decreased growth (reductions in height and weight percentile) when compared to controls.

Overdose and Emergency Response

The official regulatory documentation for Spinraza (Nusinersen) provides specific guidance regarding management in the event of suspected over-administration. A central regulatory statement is that there have been no reported human overdoses of Spinraza listed in official summaries. Consequently, specific symptom profiles, clinical manifestations, or affected physiological systems linked explicitly to an overdose are not formally documented.

Overdose Scope	Regulatory Statement Summary
Documented Manifestations	No human overdoses of Spinraza have been reported in official regulatory summaries.
Required Management	Supportive medical care should be provided, including close observation of the patient's clinical status.

Given the lack of documented overdose data, the regulatory emphasis is on immediate, mandatory action. Urgent medical attention is strictly required if there is any suspicion that too much Spinraza has been administered. This action must be taken immediately, even if the individual exhibits no immediate signs of discomfort. Official guidance across authorities mandates contacting a doctor or proceeding to the nearest Emergency Department without delay. The defined management strategy ensures the patient receives necessary medical care focused on general support and close clinical observation, as no specific antidote is known or mentioned in the official prescribing information for this therapy. The regulatory guidance is uniform across various jurisdictions, prioritizing a swift, precautionary response.

Therapeutic Uses of Spinraza

What Spinraza Treats: Main Uses and Benefits

Spinraza is used in the therapeutic management of Spinal Muscular Atrophy (SMA) in both pediatric and adult patients. The therapy is indicated for all presentations of genetically confirmed 5q SMA. It is applicable for patients in the presymptomatic stage, as well as those with severe infantile-onset (Type 1) and later-onset forms (Type 2 and Type 3). The overall benefit is associated with managing the condition's symptomatic burden.

The medicine is commonly used to help manage the primary symptom complex of SMA: progressive muscle weakness leading to functional decline. It addresses symptom clusters that may become intense or disruptive, including weakness in limbs and trunk, impaired breathing, and difficulty with swallowing. This supportive relief assists with the stabilization or support of motor function and addressing symptoms related to mobility, which may help patients cope more steadily with symptom fluctuations.

“This use provides support that helps ease the overall symptom burden and assists with maintaining functional stability related to breathing.”

The therapeutic goal is to support the patient during episodes of heightened discomfort and assist with maintaining functional stability.

Quick Fact: Support for Motor Function
This medicine is commonly used to address the progressive loss of motor function in SMA, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

The official regulatory criteria for Spinraza define the eligible patient population based on a specific diagnosis and age range, while also outlining conditions that require special caution or preclude administration.

Eligibility Scope

Classification	Official Regulatory Statements
Populations Allowed	Pediatric and adult patients diagnosed with Spinal Muscular Atrophy (SMA). The FDA label covers all types of SMA due to a genetic defect in the SMN1 gene on chromosome 5q.
Contraindications	None are formally listed in the US FDA prescribing information. The EMA SmPC lists hypersensitivity to the active substance (nusinersen) or any excipients as a contraindication.
Administration Restriction	The medicine must not be administered in areas of the skin where there are signs of infection or inflammation (relating to the injection site).
Pregnancy/Lactation	As a precautionary measure, it is preferable to avoid use during pregnancy; the US FDA notes that based on animal data, the drug may cause fetal harm. It is unknown if the drug is excreted in human milk, and a risk to the infant cannot be excluded.

Mandatory Monitoring

Use of Spinraza requires monitoring due to potential risks observed with this class of medicine. Physicians must perform platelet count and coagulation laboratory testing, as well as quantitative spot urine protein testing, at baseline and prior to each dose to monitor for potential bleeding complications and renal toxicity.

What should I know about interactions with other medicines?

The official interaction profile for Spinraza (Nusinersen) is primarily determined by its method of delivery. As an antisense oligonucleotide, the medicine is administered directly into the spinal canal via intrathecal injection. This specific route results in minimal systemic exposure to the liver and other major organs responsible for drug metabolism and clearance.

Due to this unique pharmacokinetic profile, authoritative government regulatory bodies, including the European Medicines Agency and the U.S. Food and Drug Administration, note that formal systemic drug interaction studies have not been conducted.

Consequently, the official prescribing information documents no known clinically relevant interactions between Nusinersen and commonly co-administered systemic medicines, foods, or supplements. The official regulatory status regarding interactions is detailed below:

Interaction Domain	Official Regulatory Documentation Status
Medicinal product categories with documented interactions	None documented.
Transporter or CYP-mediated interactions	Low likelihood; in vitro data suggests it is not a CYP450 inducer or inhibitor.
Contraindicated combinations	None listed in official documents.
Timing-based interaction rules	No mandatory separation rules are documented.

This regulatory basis relies on the absence of expected systemic effects, confirming that co-administered systemic drugs are not anticipated to significantly alter Nusinersen exposure or clearance.

Mechanism of Action

Correcting Gene Expression Through Targeted RNA Splicing

Spinraza (nusinersen) is a specialized medicine that acts as an Antisense Oligonucleotide (ASO), intervening directly at the genetic processing level within the central nervous system. Its primary mechanistic domain is targeted RNA splicing correction, where it binds specifically to the Intronic Splicing Silencer N1 (ISS-N1) sequence on the SMN2 pre-messenger RNA (pre-mRNA). This binding physically blocks inhibitory proteins, thereby modulating the splicing mechanism, promoting the inclusion of Exon 7 in the final mRNA.

Increasing Functional Motor Neuron Protein

The core mechanistic cascade of nusinersen leads directly to the increased cellular production of functional SMN protein. By promoting Exon 7 inclusion, the mechanism shifts the cellular process from producing a short, unstable protein to generating full-length, functional Survival Motor Neuron (SMN) protein. This resulting physiological effect increases the concentration of critical SMN protein within motor nerve cells. The presence of full-length SMN protein is necessary for the structural integrity and long-term viability of motor nerve cells.

Biological Constraint and Template Dependency

The drug's mechanism is fundamentally constrained by the patient's existing genetic makeup; its action depends on the SMN2 gene copy number, as this gene serves as the necessary template for the drug to act upon. The capacity for functional SMN protein generation is therefore intrinsically linked to this biological constraint, defining the ceiling for the mechanistic effect on motor neuron viability.

Dosage and Administration Information

Instruction Map: How to use Spinraza — Administration Guidelines

Administration Scope

Instruction	Detail
Route of administration	Intrathecal injection via lumbar puncture, administered by, or under the direction of, healthcare professionals experienced in the procedure.
Dosing schedule	The recommended dose is 12 mg (5 mL) per administration. Treatment begins with four loading doses followed by maintenance doses.
Preparation requirements	The vial must be allowed to warm to room temperature (25°C or 77°F) before use, without the application of external heat. The solution must not be diluted.
Age-group administration rules	Ultrasound or other imaging techniques may be considered to guide the intrathecal administration, particularly in younger patients.
Missed-dose rules	If a dose is delayed or missed, it should be administered as soon as possible, ensuring a minimum interval of 14 days between doses is maintained.
Special procedural conditions	Prior to the injection, 5 mL of cerebrospinal fluid (CSF) must be removed. The medication is administered as a bolus over 1 to 3 minutes.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Injection (Specialized Intrathecal)
Frequency pattern	Intermittent: Initial intensive phase followed by long-term, fixed-interval maintenance.
Instructional basis	Prescribing information.
Use-context constraints	Aseptic technique and specialist supervision are required for administration.

Resulting Procedural Structure

Step sequence:

The vial is allowed to warm to room temperature.
The 12 mg (5 mL) dose is withdrawn from the single-dose vial using aseptic technique.
An equivalent volume of 5 mL of CSF is removed from the patient.
The dose is administered as an intrathecal bolus over 1 to 3 minutes.
The dose is administered according to the schedule of four loading doses (Days 0, 14, 28, 63), followed by a maintenance dose once every four months.

Connection to the overall use protocol: The instructions establish a structured, two-phase regimen: an initial intensive period of four loading doses, followed by a permanent maintenance phase. The required use of the intrathecal route and the need for specialized personnel ensure the standard 12 mg dose is delivered directly to the target area. The specific procedural rules, such as CSF removal and timed bolus injection, standardize the administration conditions.

Recent Clinical Evidence

Research evidence / Overview of Studies for Spinraza

The following information summarizes the research studies conducted for Spinraza (nusinersen) to treat spinal muscular atrophy (SMA). This overview focuses on the types of evidence that exist, the study populations, and the limitations noted in the research, without providing clinical advice, personal recommendations, or safety details.

Evidence for Infantile-Onset Spinal Muscular Atrophy (Type 1)

The main research foundation for the infantile-onset population is based on randomized, double-blind, sham-controlled Phase 3 trials which were followed by open-label extension studies for longer-term monitoring. This rigorous study design was used in research exploring how symptoms change over time in infants studied for Type 1 SMA. The studies examined infants, generally aged seven months or younger, and monitored outcomes related to event-free survival and motor milestone achievement, which were measured using specialized scales. Findings describe patterns observed when comparing the treated group to the control group.

Evidence for Later-Onset Spinal Muscular Atrophy (Types 2 and 3) in Children and Adolescents

Evidence for later-onset SMA comes from intermediate-term, randomized, double-blind, sham-controlled Phase 3 trials which was evaluated in non-ambulatory children and adolescents. These studies were used in observational settings evaluating daily-life functioning. Researchers examined changes in motor function using standardized tests, such as the Hammersmith Functional Motor Scale—Expanded (HFMSE), and upper limb function (RULM). The findings indicating measurements of motor function scores were observed when comparing the treated group and the sham-control group after approximately 15 months.

Evidence for Presymptomatic Spinal Muscular Atrophy

Research for the presymptomatic population is primarily derived from single-arm, open-label studies that was observed in infants who had a genetic diagnosis of SMA but began treatment before the onset of any clinical symptoms. These studies monitored outcomes such as survival without permanent ventilation and the attainment of WHO motor milestones. The comparative evidence is lacking because these were single-arm studies without a concurrent, randomized control group, meaning data's interpretation relies heavily on comparisons to the known natural history of SMA.

What Research Gaps and Uncertainties Remain

Comparative evidence is lacking for many subgroups, particularly the adult SMA population, where evidence from large-scale controlled trials is not available. The results apply only to the populations studied, and the follow-up durations were limited in the most rigorous studies. Long-term effects are not fully established by randomized, controlled evidence, as the longest controlled trials were limited to 15 months.

How should Spinraza be stored and disposed of?

Storage and Disposal Instructions for Spinraza

Spinraza (nusinersen) must be stored under specific, mandatory conditions to maintain its stability, as defined in official regulatory labeling.

Required Storage Conditions

Condition	Requirement
Temperature	Refrigerated, between 2°C and 8°C.
Prohibited	Do not freeze.
Light Protection	Store in the original carton to protect the vial from light.
Temporary Storage	An unopened vial may be kept at room temperature (up to 30°C) for a maximum of 30 hours; it must be discarded if this time limit is exceeded.
Child Safety	Keep out of the sight and reach of children.